以臂静脉作为替代导管的髂股动脉旁路术治疗慢性肢体威胁性缺血的有效性与安全性
多中心回顾性队列研究纳入53例连续以臂静脉作为替代导管的髂股动脉旁路术,患者均为TASC C/D级慢性肢体威胁性缺血且术后感染风险增高。720天无截肢生存率71%、一期通畅率72%、二期通畅率89%、总生存率75%,30天主要不良心血管事件9.4%,30天死亡率3.8%。作者认为该术式有效安全,臂静脉可作为髂股动脉重建的适宜自体替代导管。
要点
- 臂静脉作为替代导管的髂股动脉旁路术720天无截肢生存率71%、二期通畅率89%。
- 30天主要不良心血管事件发生率为9.4%,30天死亡率为3.8%,无移植物晚期感染。
- Cox回归分析显示所分析变量与无截肢生存率之间无关联。
核心结论
- 以臂静脉作为自体导管的髂股动脉旁路术是有效且安全的手术,术后心血管并发症发生率低、无截肢生存率高。
- 臂静脉可能是髂股动脉重建中有趣且合适的自体替代导管,尤其适用于应避免使用人工血管或人工血管不可得的情况。
研究设计与样本
- 多中心、回顾性队列研究,纳入53例连续以臂静脉作为替代导管的髂股动脉旁路术。
- 手术实施时间为2013年11月至2021年11月,仅纳入TASC髂主动脉C或D级且术后手术感染风险增高的慢性肢体威胁性缺血患者。
- 人口学、临床变量和结局数据来自前瞻性数据库。
主要发现
- 平均年龄64.2±8.4岁,男性为主,中位随访615天。
- 所有患者均为慢性肢体威胁性缺血,以组织缺损为主(n=51;96.2%),中位踝肱指数0.28。
- 大多数手术使用贵要静脉(69.8%)。
- 30天主要不良心血管事件5例(9.4%),30天死亡率3.8%。
- 720天无截肢生存率、一期通畅率、二期通畅率和总生存率分别为71%、72%、89%和75%。
临床怎么用
- 原文结论认为该术式有效安全,臂静脉可作为髂股动脉重建的自体替代导管,尤其适用于应避免使用人工血管或人工血管不可得时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The use of basilic vein in iliofemoral revascularizations was previously described in the literature as an autologous option for the treatment of vascular prosthesis infection and as a primary conduit in patients at high risk of infectious surgical complications. However, the publications available include several different indications and are limited to case reports. Therefore, the aim of this study was to evaluate the outcomes of the use of arm veins as a safe and effective autologous alternative for iliofemoral reconstruction in patients with chronic limb-threatening ischemia (CLTI) and at high risk of prosthesis infection. METHODS: We performed a multicenter, retrospective cohort study with 53 consecutive iliofemoral bypasses using arm veins as an alternative conduit. The procedures were performed between November 2013 and November 2021, exclusively for patients with CLTI classified as TASC aortoiliac C or D with increased risk of postoperative surgical infection. Demographic, clinical variables, and outcomes were collected from a prospective database. Main endpoints were amputation-free survival (AFS) and major adverse cardiovascular events. Secondary endpoints included primary and secondary patencies and overall survival. Cox regression analysis was used to identify the predictors of AFS. Postoperative surgical complications and 30-day mortality were also assessed. RESULTS: The mean age was 64.2 ± 8.4 years, with a predominance of male gender. The median follow-up period was 615 days. All patients had CLTI, with a predominance of tissue loss (n = 51; 96.2%) and a median ankle-brachial index of 0.28. The basilic vein was utilized in most procedures (69.8%). Thirty-day major adverse cardiovascular events occurred in five cases (9.4%), and the 30-day mortality rate was 3.8%. The AFS, primary patency, secondary patency, and overall survival in 720 days were 71%, 72%, 89%, and 75%, respectively. Cox regression analysis revealed no association between the variables analyzed for AFS. There was no graft late infection nor pseudoaneurysmal degeneration. CONCLUSIONS: Iliofemoral bypass using arm veins as an autologous conduit proved to be an effective and safe procedure with low incidence of postoperative cardiovascular complications and high rates of AFS in patients with CLTI. Also, this suggests that arm veins can be an interesting and suitable autologous alternative conduit for iliofemoral reconstructions, especially in cases in which a prosthesis should be avoided or when it is not available.
引用
- Giusti JCG, Rossi FH, Cury MVM, et al. Efficacy and safety of iliofemoral bypass using arm veins as an alternative conduit for chronic limb-threatening ischemia. J Vasc Surg. 2023. PMID: 37343730. doi:10.1016/j.jvs.2023.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。